TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04922333: Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery

Sponsor: Wake Forest University Health Sciences · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT04922333 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04922333 Rescue Dossier →